Crewe Advisors’s BridgeBio Pharma BBIO Stock Holding History

Crewe Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-4	Closed	-$106	–	444
2023 Q3	$106	Buy	+4	New	+$114	﹤0.01%	563

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Crewe Advisors's BBIO Position: Q4 2023 in Review

Crewe Advisors sold out of BridgeBio Pharma (BBIO) in Q4 2023, closing a stake of 4 shares — an estimated $106 sold.

Crewe Advisors first reported a position in BBIO in Q3 2023 and held it in 1 quarter. The position peaked at $106 in Q3 2023. 247 funds tracked by Wall St. Rank hold BBIO as of Q4 2023.

Crewe Advisors reported no remaining BridgeBio Pharma position as of Q4 2023 after selling out during the quarter.
Crewe Advisors sold 4 BridgeBio Pharma shares in Q4 2023, an estimated $106.
Crewe Advisors first reported a position in BridgeBio Pharma in Q3 2023 and held it in 1 quarter.
Crewe Advisors's BridgeBio Pharma position peaked at $106 in Q3 2023.
247 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2023.

Based on Crewe Advisors's 13F filing for Q4 2023, filed 9 Feb 2024.